SLC2A3 and colorectal carcinoma: The mTOR agonist MYH1485 used to activate the mTOR pathway in CRC cells showed that the expression level of GLUT3 was upregulated, thereby validating the positive promotion effect of the mTOR pathway on GLUT3.